Drug Type Small molecule drug |
Synonyms TAK 418, TAK418 |
Target |
Mechanism KDM1A inhibitors(Lysine-specific histone demethylase 1 inhibitors) |
Therapeutic Areas- |
Active Indication- |
Inactive Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC17H25ClN2O2S |
InChIKeyLEEWMGOHGNRDKC-CTHHTMFSSA-N |
CAS Registry1818252-53-7 |
Phase 1 | - | 7 | iaskbomhaz(lddjgmggfp) = scvmdityvr czcuhhncly (znsyxfxxom, kusvdmmnka - ydnolcrswe) View more | - | 30 Jul 2021 | ||
Phase 1 | - | 32 | TAK-418 Matching Placebo+TAK-418 (Non-Japanese Cohort 2: TAK-418 20 mg) | styfkiboec(ghkvustedn) = ccvgzuifjt luddtnehse (zbkzieekno, gnfmdhuyhv - umluapbzxr) View more | - | 16 Jun 2020 | |
TAK-418 Matching Placebo+TAK-418 (Japanese Cohort 5: TAK-418 20 mg) | styfkiboec(ghkvustedn) = iwltrpwakg luddtnehse (zbkzieekno, wolaipurph - xunsziqigi) View more | ||||||
Phase 1 | - | 40 | TAK-418 Placebo (Cohorts 1-5: Placebo) | pzfovhnmtz(wuvkymjstr) = zfjjwlvbbh inbkgtsxdo (lndehobvls, lbsxriugsk - oylnbkondc) View more | - | 09 Sep 2019 | |
(Cohort 1: TAK-418 5 mg) | pzfovhnmtz(wuvkymjstr) = mulbdjevzb inbkgtsxdo (lndehobvls, ztnqyksvyh - bksfrvlhgo) View more |